BRAF突变基因在前列腺癌骨转移中的表达及临床意义

发布时间：2018-06-08 07:00

本文选题：前列腺癌 + 骨转移　；参考：《南昌大学》2017年硕士论文

【摘要】：目的:通过免疫组化、PCR技术探讨BRAF基因在前列腺癌骨转移与无骨转移中的表达差异,并分析BRAF突变基因与前列腺癌骨转移之间的相关性。方法:(1)随机选取南昌大学第一附属医院2013年01月~2015年02月期间在我科经前列腺穿刺活检或手术后病理检查确诊的103例前列腺癌患者以及同时期随机选取20例前列腺良性增生患者作为研究对象,以ECT、CT/MRI或骨活检诊断骨转移,前列腺癌的临床分期根据美国肿瘤联合会(AJCC,2009年)的TNM分期标准。(2)运用免疫组织化学方法检测BRAF蛋白在前列腺癌骨转移,前列腺癌无骨转移及前列腺增生组织(前列腺肿瘤组织)中的表达情况,并分析其意义。(3)运用PCR技术检测BRAF基因在前列腺癌骨转移、前列腺癌无骨转移及前列腺增生组织(前列腺肿瘤组织)中突变的情况,并分析其意义。(4)利用SPSS19.0软件系统建立数据库并进行统计学分析,对比研究BRAF突变基因与前列腺癌骨转移的关系。结果:1、免疫组化实验结果显示:(1)BRAF蛋白在前列腺癌骨转移和前列腺癌无骨转移组织中的表达,结果显示BRAF蛋白在前列腺癌骨转移和前列腺癌无骨转移组织中的表达差异有统计学意义(P0.05)。(2)BRAF蛋白在前列腺癌骨转移和前列腺增生组织中的表达,结果显示BRAF蛋白在前列腺癌骨转移和前列腺癌增生组织中的表达差异有统计学意义(P0.05)。2、PCR实验结果显示:前列腺增生组BRAF基因无突变,前列腺癌骨转移组BRAF基因突变与前列腺癌无骨转移组BRAF基因突变相比较,结果显示BRAF基因突变在前列腺癌骨转移和前列腺癌无骨转移组织中的表达差异有统计学意义(P0.05)。结论:前列腺癌骨转移BRAF蛋白的表达高于前列腺癌无骨转移组和前列腺增生组,前列腺癌骨转移组BRAF基因突变率要明显高于前列腺癌无骨转移组,初步提示BRAF突变基因可能可以作为一个前列腺癌骨转移患者的相关因素。
[Abstract]:Objective: to investigate the difference of BRAF gene expression between bone metastases and bone metastases of prostate cancer by immunohistochemical technique and to analyze the correlation between BRAF mutation gene and bone metastasis of prostate cancer. Methods A total of 103 patients with prostate cancer confirmed by biopsy or pathological examination after operation were randomly selected from the first affiliated Hospital of Nanchang University from January 2013 to February 2015, and 20 cases were randomly selected from the same period. Patients with benign hyperplasia of glands were studied. Bone metastases were diagnosed by CT / MRI or bone biopsy. The clinical staging of prostate cancer was based on TNM staging standard of AJCC (2009). Immunohistochemical method was used to detect BRAF protein in bone metastasis of prostate cancer. Expression of BRAF gene in prostate cancer without bone metastasis and prostatic hyperplasia (prostate cancer) and its significance were analyzed. PCR technique was used to detect the expression of BRAF gene in bone metastasis of prostate cancer. The significance of mutation in prostate cancer without bone metastasis and prostatic hyperplasia (prostate cancer tissue) was analyzed, and the database was established by SPSS 19.0 software system and analyzed statistically. To study the relationship between BRAF mutation gene and bone metastasis of prostate cancer. Results the immunohistochemical results showed the expression of BRAF protein in bone metastases of prostate cancer and no bone metastasis in prostate cancer. The results showed that there were significant differences in the expression of BRAF protein between prostate cancer bone metastasis and prostate cancer without bone metastasis. The expression of BRAF protein in prostate cancer bone metastases and prostate hyperplasia tissues was significantly different. The results showed that there was significant difference in the expression of BRAF protein in bone metastases and hyperplasia of prostate cancer. The results of PCR showed that there was no mutation of BRAF gene in benign prostatic hyperplasia. The expression of BRAF gene mutation in bone metastases of prostate cancer was significantly different from that in bone metastases of prostate cancer and no bone metastases of prostate cancer (P 0.05), and the results showed that there was a significant difference in the expression of BRAF gene between the bone metastases of prostate cancer and those without bone metastasis of prostate cancer. Conclusion: the expression of BRAF protein in bone metastases of prostate cancer is higher than that in prostate cancer without bone metastasis and prostatic hyperplasia, and the mutation rate of BRAF gene in prostate cancer bone metastasis is significantly higher than that in prostate cancer without bone metastasis. These results suggest that the BRAF mutation gene may be a related factor in bone metastases of prostate cancer.
【学位授予单位】：南昌大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.25

【参考文献】